drugset / Trial / NCT00365924

A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo

NCT00365924

Completed 20 enrolled Pfizer
Non-randomizedSingle-groupOpen-label

Summary

This methodology trial will be conducted in patients with osteoporosis and will measure the changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone density following therapy with the approved drug, Forteo.

Timeline

Start
2006-12
Primary completion
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic

Indications